Measurement of progression in Alzheimer's disease: a clinician's perspective
dc.contributor.author | Gelb, Douglas J. | en_US |
dc.date.accessioned | 2006-04-19T13:54:22Z | |
dc.date.available | 2006-04-19T13:54:22Z | |
dc.date.issued | 2000-06-15 | en_US |
dc.identifier.citation | Gelb, Douglas J. (2000)."Measurement of progression in Alzheimer's disease: a clinician's perspective." Statistics in Medicine 19(11-12): 1393-1400. <http://hdl.handle.net/2027.42/34854> | en_US |
dc.identifier.issn | 0277-6715 | en_US |
dc.identifier.issn | 1097-0258 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34854 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10844704&dopt=citation | en_US |
dc.description.abstract | Patients with Alzheimer's disease (AD) and their families must confront two fundamental truths. First, AD is a uniformly progressive disease that ultimately results in debilitating cognitive impairment. Second, although there is now evidence that some medications may produce transient improvement or possibly even slowing of disease progression, there is currently no way to halt the progression of AD. Consequently, patients and their families consistently ask the following questions: 1. What new management issues can be anticipated, and when? 2. What clinical developments are atypical and merit evaluation for a superimposed problem? 3. Is the current treatment working? These questions can only be answered by referring to the natural course of AD, and specifically, information regarding measures of functional impairment and how they change over time. The information that is currently available on this topic is limited and often embodies implicit assumptions that have not been adequately tested. This information will be reviewed, and directions for future research will be outlined. Copyright © 2000 John Wiley & Sons, Ltd. | en_US |
dc.format.extent | 65108 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | John Wiley & Sons, Ltd. | en_US |
dc.subject.other | Mathematics and Statistics | en_US |
dc.title | Measurement of progression in Alzheimer's disease: a clinician's perspective | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbsecondlevel | Statistics and Numeric Data | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Social Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Neurology, University of Michigan Medical School, Ann Arbor, Michigan 48109-0316, U.S.A. ; Department of Neurology, University of Michigan Medical School, Ann Arbor, Michigan 48109-0316, U.S.A. | en_US |
dc.identifier.pmid | 10844704 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34854/1/431_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/(SICI)1097-0258(20000615/30)19:11/12<1393::AID-SIM431>3.0.CO;2-O | en_US |
dc.identifier.source | Statistics in Medicine | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.